Pfizer PFE is due to report third-quarter 2025 results on Nov. 4. All eyes will be on sales of Pfizer’s oncology drugs, which ...
Discover whether Moderna or BioNTech offers better long-term investment potential as both pivot from COVID-19 to innovative ...
Pfizer is backed by strong H1 results, a promising pipeline, improved financials, and solid valuation with long-term growth ...
Pfizer is expected to report its third-quarter results next month, and analysts are projecting a double-digit decline in its ...
At present, a total of 18 facilities across Slovakia provide vaccination with the new Comirnaty LP.8.1 vaccine. Those ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback